Dashboard
1
Flat results in Sep 25
- INTEREST(HY) At CNY 1.1 MM has Grown at 83.32%
- INVENTORY TURNOVER RATIO(HY) Lowest at 5.35 times
- DEBTORS TURNOVER RATIO(HY) Lowest at 1.85 times
2
With ROE of 15.58%, it has a fair valuation with a 4.66 Price to Book Value
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 8,241 Million (Mid Cap)
30.00
NA
1.45%
-0.62
14.50%
4.21
Revenue and Profits:
Net Sales:
286 Million
(Quarterly Results - Sep 2025)
Net Profit:
73 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.84%
0%
8.84%
6 Months
-0.27%
0%
-0.27%
1 Year
-3.57%
0%
-3.57%
2 Years
4.82%
0%
4.82%
3 Years
-18.34%
0%
-18.34%
4 Years
-18.76%
0%
-18.76%
5 Years
-43.77%
0%
-43.77%
Amoy Diagnostics Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.57%
EBIT Growth (5y)
13.54%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.58
Tax Ratio
11.23%
Dividend Payout Ratio
46.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
33.98%
ROE (avg)
15.98%
Valuation key factors
Factor
Value
P/E Ratio
30
Industry P/E
Price to Book Value
4.66
EV to EBIT
25.21
EV to EBITDA
21.04
EV to Capital Employed
10.08
EV to Sales
6.75
PEG Ratio
3.38
Dividend Yield
1.36%
ROCE (Latest)
39.98%
ROE (Latest)
15.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
286.30
305.00
-6.13%
Operating Profit (PBDIT) excl Other Income
62.20
103.10
-39.67%
Interest
0.40
0.40
Exceptional Items
1.50
1.80
-16.67%
Consolidate Net Profit
73.50
83.40
-11.87%
Operating Profit Margin (Excl OI)
217.40%
290.70%
-7.33%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is -6.13% vs 22.98% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -11.87% vs 77.45% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,105.40
1,040.20
6.27%
Operating Profit (PBDIT) excl Other Income
334.30
327.60
2.05%
Interest
1.70
1.60
6.25%
Exceptional Items
-17.20
-5.00
-244.00%
Consolidate Net Profit
254.90
261.50
-2.52%
Operating Profit Margin (Excl OI)
248.90%
258.10%
-0.92%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 6.27% vs 23.88% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -2.52% vs -1.06% in Dec 2023
About Amoy Diagnostics Co., Ltd. 
Amoy Diagnostics Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






